Iantrek has reached an exciting milestone as we transition from development of our bio-interventional technologies to ...

Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two U.S. Phase II clinical trials ...

Himani Goyal, MD, takes glaucoma care to the next level by embracing advancements that extend beyond traditional treatment ...

Indentation gonioscopy and dark room SS-OCT were performed. Gonioscopic angle closure was defined as non-visibility of the posterior trabecular meshwork in ≥180° of the angle. For each subject, all ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

Sight Sciences (NASDAQ:SGHT – Get Free Report) had its target price dropped by analysts at Stifel Nicolaus from $6.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga ...

Patients with glaucoma who are using prostaglandin F (FP) receptor agonists to control their disease may experience ...

Recognition of specific antigen through the B-cell receptor (BCR) stimulates the activation of B cells, which ultimately results in the production of high-affinity antibodies and the provision of ...